Sub: Reconciliation of Share Capital Audit Report for the second quarter ended on September 30, 2018

Transcription

1 GlaxoSmithKline Consumer Healthcare Ltd Floor, One Horizon Center Sector 43, DLF Phase 5, Golf Course Road Gurugram (Haryana), India October 08, 2018 T F E contact.4.gsk@gsk.com The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai The Listing Compliance Department National Stock Exchange of India Limited Exchange Plaza, C - 1, Block - G Sandra Kurla Complex, Sandra Mumbai Sub: Reconciliation of Share Capital Audit Report for the second quarter ended on September 30, 2018 Dear Sir I Madam, Pursuant to Regulation 55A of SEBI (Depositories & Participants) Regulations, 1996, we are enclosing herewith the Reconciliation of Share Capital Audit Report for the Second Quarter ended September 30, Please take the same on your record. Thanking You, For GlaxoSmithKline Consumer Healthcare Limited _/1~ Shanu Saksena \12. Company Secretary CIN: L24231PB1958PLC Registered Office Patiala Road Nabha (Punjab), India

2 10/8/2018 GSK55... html Scrip code* NSESymbol MSEI Symbol!SIN Name of the company* Registered office address* Registered office state* Registered office city* Registered office district* RECONCILIATION OF SHARE CAPITAL AUDIT GSKCONS NOT LISTED INE264A01014 GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED Registered office address PATIALA ROAD, NABHA PUNJAB NABHA NABHA Registered office pin code* Registered office contact ISD Code* STD Code* Number* number* Registered office fax Registered office countty* INDIA Registered office website Registered office Same as above C01Tespondence address Correspondence state CoITespondence city Correspondence district No Correspondence address 24th FLOOR, ONE HORIZON CENTER, SECTOR 43, DLF PHASE 5, GOLF COURSE ROAD, GURUGRAM HARYANA GURUGRAM GURUGRAM C01Tespondence pin code CotTespondence contact!sd Code STD Code Number number , Correspondence fax Correspondence country Correspondence INDIA investor.2.co@gsk.com Repo1ting quarter* Face value* 10 Stock Exchange Details : Name of stock Exchange Listed Capital % Of total issued capital Name of other stock exchanges where the company's securities are listed BSELtd National Stock Exchange.oflndia Ltd(NSE) Remarks file:///z:/personal%20folders/rishubh/ /stock%20exchange%20submissions/regulation%2055/bse/gsk55... html 1/5

3 10/8/2018 GSK htrnl Capital Details : Number of shares % Of total issued capital Issued capital* Listed capital (BSE) (As per company records)* Held in dematerialised form in CDSL * Held in dematerialised form in NSDL * Physical* Total no.of shares* Reasons for difference if any, Between issued capital and listed capital* 0 Reasons for difference if any, Between issued capital and total number of shares* 0 Reasons for difference if any, Between listed capital and total number of shares* 0 fi le:///z:/personal%20folders/rishubh/ /stock%20exchange%20subrnissions/regulation%2055/bse/gsk55... html 2/5

4 10/8/2018 GSK html Certifying the details of changes in share capital during the quarter under consideration as per Table below: Whether changes during the quarter* Register of members is updated* Yes Ifi1ot, Updated upto which date Reference of previous quarter with regards to excess dematerialised shares,lfany. Has the company resolved the matter (excess dematerialised shares mentioned above) in the cunent quaiter?* If not, Reason why? NIL NA fi le:///z:/personal%20folders/rishubh/ /stock%20exchange%20submissions/regulation%2055/bse/gsk55... html 3/5

5 10/8/2018 GSK55... html Mentioned the total no.of requests, If any, confirmed after 21 days and the total no.of requests pending beyond 21 days with the reasons for delay Total no.of demat requests No.of requests* No.of shares* Reasons for delay Confumed after 21 days* 0 0 Pending for more than 21 days* 0 0 Remarks Compliance Officer Details Name of the compliance officer* Shanu Saksena Designation* Company secreta1y Membership Nos 9733 Telephone no.* Fax no id* shanu.s.saksena@gsk.com file:///z:/personal%20f olders/rishubh/ /stock%20exchange%20submissions/regulation%2055/bse/gsk html 4/5

6 10/8/2018 GSK55... html CA/CS* Name of ce1tifying auditor* Company secretaiy S. ANAND S.S.RAO Date of issue of report* Certifying Auditor Details Address* 511, KANCHANJUNGA BLOCK, ADITYA ECLAVE, AMEERPET, HYDERABAD City* Pincode* HYDERABAD Contact no.* Fax no Membership no Firms registration number of audit firm Name of the fom* COP number 5687 S. ANAND S.S.RAO Appointment of common agency for share registry work* NameofRTA SEBI registration no. Address State City Registrar and Share Transfer Agent Details Pincode Yes KARVY COMPUTERSHARE PRIVATE LIMITED INR l KARVY SELENIUM TOWER B, PLOT 31-32, GACHIBOWLI, FINANCIAL DISTRICT HYDERABAD NANAKRAMGUDA Contact no Fax number ofrta id einward.ris@karvy.com Website Address Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE) fi le:///z:/personal%20folders/rishubh/ /stock%20exchange%20submissions/regulation%2055/bse/gsk html 5/5

7 Us S ANAND SS RAO M.Com., LLB., F.C.S COMPANY SECRETARY IN PRACTICE Flat No.511, Kanchanjunga Adltya Enclave, Ameerpet, Hyderabad Mobile Tele Fax anandssrao@gmail.com Website RECONCILIATION OF SHARE CAPITAL AUDIT REPORT FOR THE QUARTER ENDED Report for quarter ended 2. ISIN 3. Face Value 4. Name of the Company 5. Registered Office Address 6. Correspondence Address 7. Telephone and Fax Nos. 8 Address 9. Name of the Stock Exchange where the company's Securities are listed: INE264A01014 Rs. I 0/- each GlaxoSmithKline Consumer Healthcare Limited Patiala Road, Nabha th Floor, One Horizon Center, DLF Phase 5, Golf Course Road, Gurgaon , India Tel Fax shanu.s.saksena@gsk.com Bombay Stock Exchange Limited National Stock Exchange of India Limited Number of Shares % of Total Issued Capital 10. Issued Capital Listed Capital (Exchange Wise) All (as per company records) 12. Held in dematerialised form in CDSL Held in dematerialised form in.nsdl Physical Total No. of Shares ( ) Reasons for differences if any, between I NA (10&11),(10&15),(11&15) ' ' 17. Certifying the details of changes in share capital during the quarter under consideration as per Table below: Particulars No. of Applied/ Listed on Stock Whether Whether In-principle Shares Not Exchange intimated intimated approval Pending Applied for (Specify name) to CDSL tonsdl from Stock listing Exchange(s) (Specify Names) NIL 18. Register of Members is updated (Yes /No) -YES- If not, updated upto which date -N.A-

8 19. Reference of previous quarter with regard to excess dematerialized shares, if any: 20. Has the Company resolved the matter mentioned in Point No.19 above, in the current quarter? If not reason why? -NA- 21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. ofrequests pending b evon dld 2 avs wit "hh t e reasons f<dl or e av. - NIL - No. ofrequests No. of shares Reasons for delay Confirmed after 21 days Pending for more than 21 days 22. Name, Telephone & Fax No. of Compliance Officer of the company 23. Name, Address, Telephone & Fax No., Regn no. of the Auditor 24. Appointment of common agency for share registry work (if yes, name and address) Ms. Shanu Saksena, Company Secretary-Appointed wef Ph : Fax: shanu.s.saksena@gsk.com Auditor of this Report: S.ANAND S.S.RAO Company Secretary in Practice, C.P. No.5687,M.No.FCS , Kanchanjunga Block, Aditya Enclave, Ameerpet, Hyderabad Phone: (M) Phone No: Fax No Karvy Computershare Private Limited, Karvy Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad Phone No. (91 40) Any other detail that the auditor may like to provide, (e.g. BIFR Company, delisting from Stock Exchange, company changed its name etc.:- NIL Place: Hyderabad, Date: ~ S. Anand SS Rao, Company Secretary in Practice, CP.No.5687 I FCS No.5716.